Unknown

Dataset Information

0

Inflammation's Association with Metabolic Profiles before and after a Twelve-Week Clinical Trial in Drug-Naive Patients with Bipolar II Disorder.


ABSTRACT:

Unlabelled

Inflammation is thought to be involved in the pathophysiology of bipolar disorder (BP) and metabolic syndrome. Prior studies evaluated the association between metabolic profiles and cytokines only during certain mood states instead of their changes during treatment. We enrolled drug-naïve patients with BP-II and investigated the correlation between changes in mood symptoms and metabolic indices with changes in plasma cytokine levels after 12 weeks of pharmacological treatment. Drug-naïve patients (n?=?117) diagnosed with BP-II according to DSM-IV criteria were recruited. Metabolic profiles (cholesterol, triglyceride, HbA1C, fasting serum glucose, body mass index (BMI) and plasma cytokines (TNF-?, CRP, IL-6, and TGF-?) were measured at baseline and 2, 8, and 12 weeks post-treatment. To adjust within-subject dependence over repeated assessments, multiple linear regressions with generalized estimating equation methods were used. Seventy-six (65.0%) patients completed the intervention. Changes in plasma CRP were significantly associated with changes in BMI (P?=?1.7E-7) and triglyceride (P?=?0.005) levels. Changes in plasma TGF-?1 were significantly associated with changes in BMI (P?=?8.2E-6), cholesterol (P?=?0.004), and triglyceride (P?=?0.006) levels. However, changes in plasma TNF-? and IL-6 were not associated with changes in any of the metabolic indices. Changes in Hamilton Depression Rating Scale scores were significantly associated with changes in IL-6 (P?=?0.003) levels; changes in Young Mania Rating Scale scores were significantly associated with changes in CRP (P?=?0.006) and TNF-? (P?=?0.039) levels. Plasma CRP and TGF-?1 levels were positively correlated with several metabolic indices in BP-II after 12 weeks of pharmacological intervention. We also hypothesize that clinical symptoms are correlated with certain cytokines. These new findings might be important evidence that inflammation is the pathophysiology of clinical symptoms and metabolic disturbance in BP-II.

Trial registration

ClinicalTrials.gov NCT01188148.

SUBMITTER: Lee SY 

PROVIDER: S-EPMC3695222 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature

altmetric image

Publications

Inflammation's Association with Metabolic Profiles before and after a Twelve-Week Clinical Trial in Drug-Naïve Patients with Bipolar II Disorder.

Lee Sheng-Yu SY   Chen Shiou-Lan SL   Chang Yun-Hsuan YH   Chen Po See PS   Huang San-Yuan SY   Tzeng Nian-Sheng NS   Wang Yu-Shan YS   Wang Liang-Jen LJ   Lee I Hui IH   Wang Tzu-Yun TY   Yeh Tzung Lieh TL   Yang Yen Kuang YK   Hong Jau-Shyong JS   Lu Ru-Band RB  

PloS one 20130627 6


<h4>Unlabelled</h4>Inflammation is thought to be involved in the pathophysiology of bipolar disorder (BP) and metabolic syndrome. Prior studies evaluated the association between metabolic profiles and cytokines only during certain mood states instead of their changes during treatment. We enrolled drug-naïve patients with BP-II and investigated the correlation between changes in mood symptoms and metabolic indices with changes in plasma cytokine levels after 12 weeks of pharmacological treatment.  ...[more]

Similar Datasets

| S-EPMC4998429 | biostudies-literature
| S-EPMC7456987 | biostudies-literature
| S-EPMC3637095 | biostudies-literature
| S-EPMC8380964 | biostudies-literature
| S-EPMC8090770 | biostudies-literature
| S-EPMC3304683 | biostudies-literature
| S-EPMC6473794 | biostudies-literature
| S-EPMC7299052 | biostudies-literature
| S-EPMC7244116 | biostudies-literature
| S-EPMC7118970 | biostudies-literature